Why the study?
Do P2Y12 receptor inhibitors alone or in combination with aspirin improve secondary prevention of noncardioembolic stroke?
Do P2Y12 receptor inhibitors alone or in combination with aspirin improve secondary prevention of noncardioembolic stroke?
Short-term dual antiplatelet therapy with clopidogrel and aspirin initiated early after ischemic stroke or TIA due to large artery atherosclerosis is an efficient strategy for secondary prevention.
Supports early short-term DAPT in large-artery noncardioembolic stroke; leaves open optimal regimens and head-to-head P2Y12 comparisons.
INTRODUCTION: Ischemic stroke (IS) is a major cause of death and disability worldwide. The P2Y12 receptor plays a critical role in the formation of a stable thrombus leading to ischemic complications. Therefore, P2Y12 receptor inhibitors constitute a major antiplatelet strategy in the secondary prevention of IS. AREAS COVERED: We searched articles about P2Y12 receptor inhibitors and stroke in PubMed published until December 2014. This is a comprehensive review of the role of P2Y12 receptor inhibitors alone and in combination with aspirin in the secondary prevention of noncardioembolic stroke. EXPERT OPINION: The potential benefit of more potent antiplatelet therapy for secondary stroke prevention must be weighed against the risk of bleeding in patients with IS. Short-term (≤ 3 months) dual antiplatelet therapy with clopidogrel and aspirin that is initiated early after IS or transient ischemic attack due to large artery atherosclerosis appears most efficient.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: